Akira Mima

Jun 27, 2024 | iv.iiarjournals.org | Akira Mima |Takahiro Nakamoto |Yuta Saito |Keishi Matsumoto

Key Words:Vildagliptindipeptidyl peptidase-4 (DPP-4) inhibitorsdiabetic kidney disease (DKD)fasting blood glucosehemoglobin A1c (HbA1c)Diabetic kidney disease (DKD) is a major diabetic vascular complication, associated with a high risk for morbidity and mortality (1, 2). According to the International Diabetes Federation, 463 million people had diabetes in 2019, with a predicted growth in prevalence to around 700 million by 2045.